Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020
 
NCT04322123
RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
221/227 safety concern
  • statistically significant 74 % increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
HC-nCoV (Shanghai), 2020
 
NCT04261517
RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
15/15 inconclusive
    NCT04333654, 2020
     
    NCT04333654
    RCThydroxychloroquinestandard of careCOVID-19 mild to moderateNA
    -/- inconclusive
      Zhaowei Chen, 2020
       
      ChiCTR2000029559
      RCThydroxychloroquinestandard of careCOVID-19 mild to moderatehigh
      31/31 suggested
      • suggested 2.4-fold increase in clinical improvement but with a low degree of certainty due to high risk of bias
      • suggested 2.4-fold increase in radiologic improvement (7-day) but with a low degree of certainty due to high risk of bias
      Zhaowei Chen, 2020
       
      ChiCTR2000029559
      RCThydroxychloroquinecontrolCOVID-19 mild to moderatehigh
      31/31 inconclusive
        Min, 2020 OBShydroxychloroquinecontrolCOVID-19 mild to moderateNA
        20/20 inconclusive

          PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
          Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).